As part of our series focussing on available medicines in Australia, we have added a product review of the use of enfortumab vedotin for the treatment of locally advanced or metastatic urothelial cancer.
This publication discusses current management of urothelial cancer, indications and dosage of enfortumab vedotin, adverse effects and the evidence supporting its use. It also provides commentary from Associate Professor Andrew Weickhardt, medical oncologist at the Olivia Newton-John Cancer and Wellness Centre in Melbourne.
Please login below to download this issue (PDF)